ArticleFrontiers in microbiology2025
Molecular insights of drug-resistant tuberculosis: genetic mutations and their profile.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive Analysis of Drug-Resistant Tuberculosis: Integrating Molecular Markers, Clinical Governance, and Community-Engaged Education in Rural South Africa.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug-resistant tuberculosis (DR-TB) poses a significant public health threat, with molecular diagnostics playing a pivotal role in understanding the genetic mechanisms of resistance. This study focuses on the patterns of genetic mutations observed in DR-TB cases, with the aim to identify key mutations associated with resistance to rifampicin (RIF) and isoniazid (INH). Methodology: A total of 6,954 non-duplicate clinical samples were obtained from individuals of all age groups, categorized as TB and DR-TB, from seven linked districts between June 2022 and May 2024. The samples were transported under cold chain conditions to an intermediate reference laboratory. TB was confirmed using fluorescence microscopy, and 1,998 sputum-positive samples were analyzed using line probe assay for characterization of genetic mutations. Results: Among the analyzed cases, a total of 136 cases of DR-TB were identified. This included 57 cases (41.92%) of multidrug-resistant TB (MDR-TB), 73 cases (53.68%) of INH monoresistance, and 6 cases (4.4%) of RIF monoresistance. The analysis revealed a high prevalence of Conclusion: The high prevalence of mutations such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.